$ALT

Despite Recent Gains, Altimmune Insiders Are Still Down US$29k

This article states that despite some recent positive share price movement, Altimmune insiders are still collectively down US$29k on their investments over the last year. This is primarily due to a significant share price decline, meaning recent share purchases by insiders have not yet compensated for previous losses.

Original reporting
Published Apr 7, 2026, 8:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 7, 2026, 8:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ALT
Neutral
medium confidence
Mentioned
$ALT
alphai data visualization · based on Moomoo
Decision brief

The 30-second read

$ALTNeutralLow
01

Why it matters

The insider trading data signals cautious sentiment, which may influence short-term trading decisions.

02

Market read

The news has limited immediate trading impact but provides insight into insider sentiment and potential valuation concerns.

03

What to watch

Recent share price decline could be due to sector-wide issues or company-specific challenges not fully captured in insider trading data.

Timing: short-term

Background

The article discusses insider trading losses in Altimmune amid recent share price declines, suggesting ongoing valuation challenges.

Company-level read

Ticker impact

$ALTNeutralMedium confidence
Context

The news highlights insider trading activity and recent share price decline for Altimmune.

Expected impact

Limited immediate impact; potential for short-term rebound if positive news continues, but overall sentiment remains cautious.

Evidence & confidence

The insider trading data suggests a cautious outlook; recent gains may not be sufficient to reverse overall negative trend.

Market effects

Potential cautious sentiment in the biotech and life sciences sectors due to insider trading and share decline.

Minimal regional impact; company-specific news.

Limited global relevance; pertains to a specific biotech company.

Counterpoint

The insider losses may indicate undervaluation, presenting a potential buying opportunity for long-term investors.

Key entities

  • Altimmune

    Biotech company focused on immune-modulating therapies.

Related articles

$ALTMedAI 8/10

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

$ALTMedAI 8/10

Why is Altimmune stock surging today? By Investing.com

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.

$ALTMedAI 8/10

Altimmune stock surges 18% on positive trial results By Investing.com

Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.